Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what’s new and why it matters in just 5 minutes.
Catch up on the day’s biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider’s guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: Niels Wenstedt/BSR Agency via Getty Images
Allocations of Johnson & Johnson’s coronavirus vaccine will plummet by 80% next week, according to data released by the Centers for Disease and Control Prevention.
Why it matters: J&J’s single-dose shot is viewed as key to U.S. efforts to vaccinate enough Americans to reach herd immunity as soon as possible. A spokesperson told the Wall Street Journal that J&J is still aiming to meet its goal of delivering 100 million doses by June.
By the numbers: 4.9 million J&J doses were allocated to states, territories and federal agencies this week. Next week, that number will plunge to 700,000, according to the CDC.
- It’s unclear what caused the sharp decline, but federal officials have warned that supply will fluctuate week to week, according to the WSJ.
- The week of March 1 saw 2.8 million doses distributed, while the following two weeks’ supply fell to around 400,000 to 500,000 doses per week.
The big picture: Manufacturing challenges have plagued J&J from the start, heightening concerns that the company won’t be able to meet its goals of 100 million U.S. doses by mid-year and up to 1 billion by the end of 2021.
- Some states are already rewriting their distribution plan ahead of next week’s decrease in supply. Several have publicly committed to reopening by a certain date.
- A plant in Baltimore recently ruined 15 million J&J vaccines, though the incident was not expected to affect deliveries nationwide.
- J&J declined to comment on next week’s supply to the WSJ.
No comments:
Post a Comment